Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
SINTX Technologies entered securities purchase agreements for a private placement of 1,882,845 units at $2.39 per unit, raising approximately $4.5 million in gross proceeds. Each unit includes one common share plus Class A and Class B warrants, each to buy one share at an exercise price of $2.14.
The warrants cover 200% of the shares issued, with Class A expiring in five years and Class B in two years and subject to revenue-based forced exercise if quarterly revenue reaches at least $2.0 million. Together with a recent $500,000 at-the-market sale, SINTX has raised about $5.0 million of equity capital, which it plans to use for working capital, commercialization, business development and other strategic opportunities.
SINTX Technologies reported that Nasdaq has notified it of noncompliance with a key listing rule. Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity, but SINTX reported about $904,000 of stockholders’ equity as of March 31, 2026.
The company also does not meet alternative Nasdaq standards based on market value of listed securities or net income. SINTX has 45 days, until July 6, 2026, to submit a plan to regain compliance and could receive up to 180 days from the notice date if Nasdaq accepts the plan. The notice does not immediately affect the listing or trading of the common stock, and SINTX is exploring equity financing and other balance sheet initiatives, though completion is not assured.
SINTX Technologies reported Q1 2026 revenue of $380,000 and a net loss of $2.8 million, as it continues investing in commercialization of its silicon nitride medical and industrial products.
Cash fell to $1.9 million with operating cash use of $2.5 million, and accumulated deficit reached $295 million. Management highlights new FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System and initial related revenue, plus growth in industrial applications.
However, the company states that substantial doubt exists about its ability to continue as a going concern over the next 12 months, despite cost actions, the TA&T divestiture, a sublease expected to save about $1.0 million, and remaining capacity of $5.7 million under its at-the-market equity program.
Sintx Technologies, Inc. President Robert Ryan Elmore received a grant of 4,910 shares of common stock. The shares were acquired as a compensation-related award at a reported value of $2.885 per share and are now held directly, bringing his direct ownership to 4,910 shares.
SINTX Technologies is an advanced ceramics company focused on silicon nitride biomaterials for spine, foot and ankle, dental, joint, antipathogenic, aerospace and industrial applications. Its silicon nitride products are designed to promote bone growth, resist bacteria and viruses, and improve imaging compared with metals and polymers.
The company reported a net loss of $10.4 million for the year ended December 31, 2025, with an accumulated deficit of $292.1 million and cash and cash equivalents of $4.1 million. As of March 13, 2026, it had 4,121,727 common shares outstanding and 32 employees, and maintains broad patent coverage over its silicon nitride technologies.
Elmore Robert Ryan reported acquisition or exercise transactions in this Form 4 filing.
Sintx Technologies, Inc. reported that President Robert Ryan Elmore received a grant of 107,143 restricted stock units (RSUs) on common stock. The award was granted under the company’s 2025 Equity Incentive Plan as equity-based compensation, not an open-market share purchase or sale.
Each RSU represents the right to receive one share of common stock upon vesting. According to the grant terms, 20% of the RSUs vested immediately, with the remaining units vesting in additional 20% installments every six months, aligning his compensation more closely with long-term company performance.
Sintx Technologies director Christopher Michael Lyons reported open-market purchases of the company’s common stock. He bought 7,534 shares at $2.90 per share on March 2, 2026 and 758 shares at $2.96 per share on February 25, 2026, bringing his direct holdings to 8,292 shares.
Sintx Technologies, Inc. director Jay M Moyes reported an open-market purchase of 1,000 shares of common stock at $2.91 per share on February 23, 2026. Following this transaction, his directly owned Sintx common stock holdings increased to 4,000 shares.
Sintx Technologies director Mark Lewis Anderson bought additional company stock in the open market. On February 18, 2026, he purchased 3,000 shares of Sintx Technologies common stock at a price of $3.02 per share. After this transaction, his directly held stake increased to 18,000 shares.
SINTX Technologies reported a leadership change and new executive employment terms. Effective March 16, 2026, Eric Olson will stop serving as President but will remain Chairman of the Board and Chief Executive Officer. On the same date, Ryan Elmore will become President and report to the CEO.
Elmore brings over 20 years of leadership experience in medical device and life sciences businesses, including senior commercial and international roles at Invibio, a division of Victrex plc. His executive employment agreement includes a base salary of $375,000 per year, a target annual cash bonus of 35% of base salary (with his first-year bonus guaranteed), and a $100,000 sign-on bonus payable at the start of employment.
Upon starting, he will also receive restricted stock units with a grant date value of $300,000, with 20% vesting immediately and the rest vesting in equal installments over 24 months, subject to continued employment, plus eligibility for additional equity awards tied to international business milestones. If his employment is terminated by the company without cause or by him for good reason, he is entitled to accrued compensation, a cash severance equal to two times his base salary plus target bonus, and up to 24 months of continued health coverage or equivalent cash payments, with enhanced protections in certain change in control situations.